ReviewChest2021
Pulmonary Thrombosis and Thromboembolism in COVID-19.
Review in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Acquired Hemophilia A after SARS-CoV-2 Infection: A Case Report and an Updated Systematic Review.Biomedicines · 2023Pooled it
- SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in Scnn1b-Tg mice.JCI insight · 2026Article
- Respiratory Organ-on-a-Chip for Disease Modeling: From Architecture to Functional Integration.Advanced healthcare materials · 2026Review
- Shunt estimation in pneumonia of different aetiologies: a non-invasive physiological assessment.BMJ open respiratory research · 2026Article
- Effects of Clot Burden and Distribution on Pulmonary Embolism Response Team Patients.CHEST pulmonary · 2026Article
- Effectiveness and Safety of COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Retrospective Cohort Study.Korean circulation journal · 2026Article
- The immunothrombosis pathway linking pulmonary disease to stroke and neurodegeneration: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Prevalence and effects of pulmonary embolism on hospital outcomes among COVID-19 patients.BMC research notes · 2025Article
- Galloylated polyphenols represent a new class of antithrombotic agents with broad activity against thiol isomerases.Journal of thrombosis and haemostasis : JTH · 2025Article
- Treatment of Bleomycin-induced Pulmonary Fibrosis by Intratracheal Instillation Administration of Ellagic Acid-Loaded Chitosan Nanoparticles.AAPS PharmSciTech · 2025Article
- Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry.Scientific reports · 2025Observational
- Prognostic factors in hospitalized patients with COVID-19 pneumonia and effectiveness of prophylactic anticoagulant therapy: a single-center retrospective study.BMC infectious diseases · 2025Article
- Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism.The Journal of infectious diseases · 2025Article
- In-Hospital Pulmonary Thromboembolism Development by Disease at Admission - A Nationwide, Retrospective, Observational Study Using Japanese Claims Data.Circulation reports · 2025Article
- Prediction of pulmonary embolism by an explainable machine learning approach in the real world.Scientific reports · 2025Article
- Thromboelastography in COVID-19 patients: An observational study in the South African context.African journal of laboratory medicine · 2025Article
- Coagulation and Inflammatory Indicators in Pneumonia Patients with Venous Thromboembolism: A Propensity-Score Matching Study.Journal of inflammation research · 2025Article
- Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin.PloS one · 2025Article
- Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19, the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The predilection for thrombosis in COVID-19 may be driven by at least two distinct, but interrelated, processes: a hypercoagulable state responsible for large-vessel thrombosis and thromboembolism and direct vascular and endothelial injury responsible for in situ microvascular thrombosis. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism (PE) and COVID-19 pneumonia share many signs and symptoms, diagnosing PE in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19 and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard VTE prophylaxis. In this review, the epidemiologic and pathophysiologic features, diagnosis, and treatment of COVID-19 pulmonary thrombosis and thromboembolism are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.